BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2476 related articles for article (PubMed ID: 32207804)

  • 1. Nonalcoholic Steatohepatitis: A Review.
    Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
    JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.
    Roeb E; Geier A
    Z Gastroenterol; 2019 Apr; 57(4):508-517. PubMed ID: 30965381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME
    JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of bariatric surgery in the management of nonalcoholic steatohepatitis.
    Seymour KA; Abdelmalek MF
    Curr Opin Gastroenterol; 2021 May; 37(3):208-215. PubMed ID: 33769376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Future of Nonalcoholic Fatty Liver Disease Treatment.
    Mazhar K
    Med Clin North Am; 2019 Jan; 103(1):57-69. PubMed ID: 30466676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
    Shelley K; Articolo A; Luthra R; Charlton M
    BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Younossi ZM; Loomba R; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Chalasani NP; Anstee QM; Kowdley KV; George J; Goodman ZD; Lindor K
    Hepatology; 2018 Jul; 68(1):361-371. PubMed ID: 29222911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease.
    López IC; Aroca FG; Bernal MDF; Mompeán JAL; Bernal ÁB; Martínez AMH; Barba EM; Velasco JAN; Paricio PP
    Obes Surg; 2017 Sep; 27(9):2347-2353. PubMed ID: 28229316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.
    Gottlieb A; Mosthael W; Sowa JP; Canbay A
    Digestion; 2019; 100(2):79-85. PubMed ID: 30537758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bariatric Surgery in NAFLD.
    Chauhan M; Singh K; Thuluvath PJ
    Dig Dis Sci; 2022 Feb; 67(2):408-422. PubMed ID: 34981313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Watanabe S; Hashimoto E; Ikejima K; Uto H; Ono M; Sumida Y; Seike M; Takei Y; Takehara T; Tokushige K; Nakajima A; Yoneda M; Saibara T; Shiota G; Sakaida I; Nakamuta M; Mizuta T; Tsubouchi H; Sugano K; Shimosegawa T; ;
    J Gastroenterol; 2015 Apr; 50(4):364-77. PubMed ID: 25708290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
    Alswat K; Aljumah AA; Sanai FM; Abaalkhail F; Alghamdi M; Al Hamoudi WK; Al Khathlan A; Al Quraishi H; Al Rifai A; Al Zaabi M; Babatin MA; Estes C; Hashim A; Razavi H
    Saudi J Gastroenterol; 2018; 24(4):211-219. PubMed ID: 29956688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction.
    Mathews SE; Kumar RB; Shukla AP
    Curr Opin Endocrinol Diabetes Obes; 2018 Oct; 25(5):315-320. PubMed ID: 30074500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Features of nonalcoholic steatohepatitis in severely obese children and adolescents undergoing sleeve gastrectomy.
    Alqahtani A; Elahmedi M; Alswat K; Arafah M; Fagih M; Lee J
    Surg Obes Relat Dis; 2017 Sep; 13(9):1599-1609. PubMed ID: 28600116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
    Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
    Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis.
    Henry ZH; Argo CK
    Gastroenterol Clin North Am; 2020 Mar; 49(1):45-62. PubMed ID: 32033764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 124.